

OncoMethylome Expands its Amsterdam Laboratory

Colorectal Cancer Screening Program and Service Testing Capabilities Strengthened

Liege (Belgium) – March 7, 2007, 8:00am CET – OncoMethylome Sciences (Euronext: ONCO) announced today that it has significantly expanded its Amsterdam laboratory operations. The expansion involved hiring of 10 additional scientists experienced in the field of molecular diagnostics, purchase of necessary molecular laboratory equipment, obtaining ISO laboratory certification, and leasing approximately 1000 m² of laboratory space from the Academic Medical Center (AMC) in Amsterdam. The expansion was necessary to support OncoMethylome's colorectal cancer program and to enhance its clinical trial testing services.

In the area of colorectal cancer, OncoMethylome is developing novel, non-invasive, molecular methylation tests to screen for colorectal cancer. The tests are performed on DNA isolated from stool or blood samples. The colorectal cancer program is concentrated in the company's Amsterdam laboratory and is financially supported by the SenterNovem agency of the Dutch Ministry of Economic Affairs.

In the area of personalized treatment, OncoMethylome is developing tests that predict whether a drug treatment is likely to be effective for a specific patient. The expansion of the Amsterdam laboratory provides OncoMethylome with the required capacity and ISO certification for performing clinical trial testing services in-house.

Furthermore, the Amsterdam laboratory is foreseen to play an increasing role in facilitating OncoMethylome's research collaborations with leading Dutch oncologists and medical research centers. The company's current collaborators in the Netherlands include the Amsterdam VU Medical Center, the Research Institute Growth and Development (GROW) at the Maastricht Medical Center, and the University of Groningen.

Herman Spolders, CEO of OncoMethylome commented "Colorectal cancer screening tests and personalized treatment products are an important part of our product development pipeline. This expansion allows us to align our resources with our product development priorities and to continue working closely with our Dutch research collaborators. "

About Colorectal Cancer Screening

Colorectal cancer is the second leading cause of cancer death, mainly because it is a very common cancer and is often diagnosed at an advanced stage. On average, one out of 18 people develops colorectal cancer during his or her lifetime, amounting to over 300,000 new diagnoses each year in Europe and the United States. When colorectal cancer is detected in early stages of development, the average survival rate five years after diagnosis is more than 90%. If the cancer is detected late, the

survival rate drops to 10%. Today, fewer than half of colorectal cancers are diagnosed in the early stage. These statistics underline the urgency for developing non-invasive tests that screen for this common and deadly disease.

About Personalized Treatment

When assigning treatment to a newly-diagnosed cancer patient, the treating physician generally follows a standard treatment protocol, assigning the treatment that gives a favorable response in the largest proportion of patients. The physician will typically switch to an alternative treatment only once he or she observes that the patient is not responding to the standard treatment. OncoMethylome is developing personalized treatment tests that analyze the molecular make-up of a patient's tumor, and are designed to provide treating physicians with additional and valuable information about a patient's cancer at the time of diagnosis. In other words, these tests are designed to deliver useful information for selecting the most appropriate treatment at time of diagnosis, thereby assisting physicians in "personalizing" the treatment of each individual patient.

About Methylation

Methylation is a natural control mechanism that regulates gene expression in DNA. Abnormal methylation of certain genes, such as tumor suppressor genes, can silence gene expression and is often associated with cancer development as well as with response to therapeutic treatment. OncoMethylome owns proprietary technology that is highly sensitive and capable of detecting methylation at genes of interest.

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing patent-protected gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of nine products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Chemicon International Inc., and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Lucija Turcinov
Tel. +32-479-801-902
Lucija.Turcinov@oncomethylome.com

or visit www.oncomethylome.com